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Purpose: In spite of increased prostate cancer patients, little is known about the impact of treatments for prostate cancer patients 
and outcome of different treatments based on nationwide data. In order to obtain more comprehensive information for Korean 
prostate cancer patients, many professionals urged to have national system to monitor the quality of prostate cancer care. To gain its 
objective, the prostate cancer database system was planned and cautiously accommodated different views from various professions. 
Methods: This prostate cancer research database system incorporates information about a prostate cancer research including 
demographics, medical history, operation information, laboratory, and quality of life surveys. And, this system includes three different 
ways of clinical data collection to produce a comprehensive data base; direct data extraction from electronic medical record (EMR) 
system, manual data entry after linking EMR documents like magnetic resonance imaging findings and paper-based data collection 
for survey from patients. 
Results: We implemented clinical data warehouse technology to test direct EMR link method with St.  Mary’s Hospital system. Using 
this method, total number of eligible patients were 2,300 from 1997 until 2012. Among them, 538 patients conducted surgery and 
others have different treatments.
Conclusions: Our database system could provide the infrastructure for collecting error free data to support various retrospective 
and prospective studies. 
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INTRODUCTION
The National Statistics Office in Korea exclaimed that the 
prevalence of prostate cancer quadrupled between 2002 and 
2008 [1,2]. The incidence of prostate cancer in Korea increased 
up to 24.9 per 100,000 men in 2009 in comparison with 13 per 
100,000 in 2008.
 Environmental elements, western dietary habits, and the 
rise in average life expectancy are known as influential factors 
of the increased rate of prostate cancer patients. The Korean 
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objective was to develop research database system having 
easy data access, transparent scientific reproducibility, and 
interoperability between multiple centers.
MATERIALS AND METHODS
To develop database structure for multicenter prostate regis-
try system, we analyzed previously developed database sys-
tems as follows. 
1. Materials
1) CaPSURE database
According to cancer statistics in 2012, prostate cancer was the 
second leading cause of cancer-related death among men in 
the United States [4]. The CaPSURE was founded in 1995 as a 
disease registry of men with all stages of prostate cancer [5]. 
Currently, a group of 31 urological practice sites enroll pa-
tients in CaPSURE, and 40 sites including community based 
site, 4 Veterans Affairs medical centers are involved. CaPSURE 
collects approximately 1,000 clinical and patient reported 
variables. The clinical information includes history of prostate 
cancer diagnosis, biopsies, pathological findings, staging tests, 
primary and subsequent treatments, clinic procedures, Kar-
nofsky performance status scores and medications. At each 
clinic visit the urologist completes a progress record, includ-
ing current disease status, new prostate or unrelated diagno-
ses, disease signs and symptoms, and changes in medications. 
Results of imaging studies and laboratory tests are recorded 
when they are determined. In addition to the clinical data, 
the patient information is also collected. At enrollment each 
patient completes a questionnaire about sociodemographic 
parameters, comorbidities [6], and baseline health-related 
quality of life (HRQoL). Every 6 months thereafter patients are 
mailed a follow-up questionnaire, and HRQoL questionnaires 
including the Medical Outcomes Study Short Form-36 (SF-
36) [7] for general HRQoL and the University of California-Los 
Angeles Prostate Cancer Index [8] for disease specific HRQoL 
are collected. Since 1999, the survey on patient satisfaction 
with care [9,10] and fear of cancer recurrence [11] are also in-
cluded. 
2) J-Cap database
In Japan, the J-CaP database was established in 2001 with 
financial support from Japan Kidney Foundation. And the 
Japanese Urological Association commenced a study to 
gather information about hormone therapy administered to 
Japanese patients and to analyze the outcomes of treatment. 
The purposes of this study group were to gather information 
Urologic Association launched a campaign of prostate-spe-
cific antigen (PSA) screening test to raise public awareness on 
the increase in prostate cancer in Korean patients. The rapid 
increase of prostate cancer patients in Korea requires inten-
sive disease progression and management. 
 In spite of increased prostate cancer patients, little is known 
about the impact of treatments for prostate cancer patients 
and outcome of different treatments with nationwide data. In 
order to obtain more comprehensive information for Korean 
prostate cancer patients, multicenter longitudinal database 
had been proposed. There were similar projects in the United 
States and Japan. One of the most popular database for pros-
tate cancer is the Cancer of the Prostate Strategic Urologic 
Research Endeavor (CaPSURE), which is the web-based data-
base developed in 1995 for longitudinal observation of pros-
tate cancer patients in natural settings in the United States. 
This project began with ten participating health care centers 
and increased to 26 centers in one year. Currently, the CaP-
SURE is one of the most powerful prospective study groups 
for prostate cancer in the world, composed of approximately 
14,000 registered prostate cancer patients. The most recent 
mover in Asia, the Japan Study Group for Prostate Cancer 
(J-CaP), was developed in 2001. In the case of J-CaP, the da-
tabase is comprised of 17,872 prostate cancer patients from 
prospective studies and research to improve patient care. 
 Against this background, many professionals urged to have 
national system to monitor the quality of prostate cancer care 
[3]. The requirement for multicenter observational prostate 
cancer database was also proposed in Korea. Observational 
databases are useful in evaluating large amounts of data in 
a timely manner, and evaluating clinical outcomes in real 
healthcare setting. The database is also used to improve the 
quality of clinical researches because data collection can as-
sist investigators. To gain its objective, the database was care-
fully planned and cautiously accommodated different views 
from various professions.
 Our first step was to develop research database structure 
including data elements for a successful observational data-
base. We defined the important questions to which providers 
want answers, and data elements need to be captured.  
 And, the second step was to compare different ways of data 
collection and suggest more efficient methods. Data capture 
with less human effort is important step to maintain the data-
base for long period time. 
 The purpose of this study is to propose the multi center ob-
servational research database structure incorporating clinical 
factors and patient self reports and suggest effective ways of 
data collection linking with clinical information systems. Our 
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and recurrence, QoL issues, and many others. Data are collect 
for standard clinical care, which includes hormonal therapy, 
radiation therapy, chemotherapy, and surgery. Each major 
treatment type has a subset of questions asked. The major-
ity of the information is collected during the treatment state. 
With an average follow-up of 8 years and over 1,200 prostate 
specimens processed, the CPDR database is rapidly becom-
ing a national prostate cancer research resource. Their efforts 
had led to more than 300 peer-reviewed publications, numer-
ous scientific presentations, more than 20 clinical trials rang-
ing from disease prevention to QoL.
2. Methods
1) Staged approach of database structure development
Developing research data base structure for multi center 
prostate cancer research is a complex undertaking. We bench-
marked previous research project by searching PubMed 
database for prostate cancer registry system. We entered the 
keyword as “prostate cancer registry system”, “prostate cancer 
database system”, and “prostate cancer retrospective research”. 
Then, large number of articles used CaPSURE database system. 
Then, we reviewed CaPSURE database system and explore the 
similarity and difference of both systems and develop basic 
category for database system. Later, we finalized data elements 
by working together with physicians of the related departments 
and refine the set of data element. We had a weekly meeting 
with doctors from urology, pathology, radiology and radiology 
oncology for two months to explore database design structure. 
Total numbers of participants were around 20 people. Dur-
ing the meeting, we asked the participants to gain consensus 
regarding important items to which patients and providers 
want answers to understand data elements to be captured. 
Finally, our research database structure includes major out-
come results for prostate cancer such as Table 1. The database 
incorporates all information about a prostate cancer research; 
demographic data, medical history, clinical information, labo-
ratory, survey, and follow-up data. The final database results to 
include approximately 222 clinical and patient-reported items. 
Our database structure has flexibility to add new measure-
ments when appropriate and to ensure variables to compare 
outcomes across other healthcare organizations.
2) Data collection method
After determining the data elements for multicenter research, 
we then develop the strategy of data collection within time-
lines. Most of the previous research database is completed 
by manual entry of physicians or clinical research coordina-
tors or data entry staffs. This data entry method is very labor 
about the hormone therapy administered to Japanese prostate 
cancer patients living in Japan and to analyze the outcomes of 
treatment in order to create a guideline for optimal hormone 
therapy. This study analyzes different forms primary androgen 
deprivation therapy (PADT), including combined androgen 
blockade therapy, for the treatment of prostate cancer within 
Japan. The J-CaP registry is a large, multicenter, population-
based database of men newly starting PADT for prostate 
cancer. The following clinical information captured over the 
Internet; date of birth, family history, date of PSA reading, PSA 
value, PSA kit name, testosterone value, biopsy date, Gleason 
score, histological grade, clinical stage, case history, details of 
hormone therapy, whether or not there has been progress ob-
servation, whether or not surgery was carried out, date of sur-
gery, operative procedure, whether or not radiotherapy is being 
conducted, irradiation method, irradiation date, progress. 
 The interim analysis of the registration status of the patients 
and their background variables was reported in 2003 [12], 
and treatment patterns with PADT have been reported along 
with an interim analysis of prognosis in 2007 [13]. As of 2005, 
J-CaP included data for 26,272 patients from 406 institutions 
comprising 77 university hospitals (67% of those in Japan), 
267 general hospitals and 62 private hospitals. Around 50% of 
new prostate cancer patients treated with hormone therapy in 
Japan was registered with J-CaP at that time.
3) CPDR database
The Center for Prostate Disease Research (CPDR) was estab-
lished in 1992, by the United States Congress-Public Law 102-
172 [14]. The participating institutions of the CPDR are the 
Department of Defense, multisite program within the School 
of Medicine, Department of Surgery, at the Uniformed Ser-
vices University of the Health Sciences, Bethesda, MD, with 
its primary clinical program located at Walter Reed Army 
Medical Center, Washington, D.C. and a scientific laboratory 
in Rockville, MD. For this program, urologists, cancer biolo-
gists, genitor-urinary pathologists, epidemiologists, biostati-
cians, medical- and bio-informaticians are involved. The goal 
of the CPDR-Clinical Center Program is to combine prostate 
screening, clinical diagnosis, data collection, education and 
counseling, and prostate disease clinical trial research. To ad-
dress this goal, the National Multicenter Database had been 
developed. The National Multicenter Database of the CPDR 
is comprised of several military medical centers including the 
Army, Air Force, and Navy, and a civilian institution. The data 
base contains approximately 500 data fields in 48 tables that 
include registration, patient contact information, pretreat-
ment diagnosis, cancer staging, treatment types, follow-up 
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intensive and cumbersome, so it usually fails to capture rel-
evant data at early times.
 We concluded that high quality data collection strategy is 
fundamental to achieve relevant information at early times. 
Our system includes three different ways of clinical data col-
lection to produce a comprehensive data base; direct data ex-
traction from electronic medical record (EMR) system, man-
ual data entry after linking EMR documents like magnetic 
resonance imaging findings and paper-based data collection 
for survey from patients. We combine various data collection 
methods for different types of data elements. For example, 
preoperative PSA value can be collected from EMR system. 
Table 2 shows different data collection methods to include 
research data into the database system. 27% of total data ele-
ments can be collected through direct EMR link, and 70% can 
be completed through indirect EMR link. 
 Our integrated data collection and data management will 
contribute to prevent redundant entry of the same informa-
tion such as direct linking with hospital information systems 
using clinical data warehousing technique. 
3) Clinical data warehouse for direct link with EMR 
     system
Implementing the direct extraction program may decrease 
the performance of EMR system, and thus it is very difficult 
to add programs into the hospital’s operating system. We 
suggest using clinical data warehouse (CDW) technology to 
access and extract research information with less effort. The 
CDW is the method to develop clinical database that is opti-
mized for distribution, mass storage and complex query pro-
cessing [15]. It also provides comprehensive views of clinical 
data for specific purpose. A CDW can provide numerous ben-
efits to researchers with quality data collection, and decision 
support capability by quick and efficient access to patient 
information and linkage to multiple operational data sources. 
 Using CDW methodology, accurate and high quality pros-
tate cancer patients’ data can be collected from EMR system 
and feeds them to central prostate cancer registry system. All 
eligible patients with newly diagnosed prostate cancer can 
be electronically transferred into the prostate cancer registry 
database from EMR system. And all registered patient infor-
mation will be periodically updated (Fig. 1). 
RESULTS
Our prostate cancer research database system is developed 
with Microsoft SQL server running on the Microsoft NT serv-
ers and is programmed with Java for user interface develop-
Table 1. Data elements of prostate cancer database system
1. Demographics Age, sex, height, weight, body mass index
2. Medical history Operation history, preexisting comorbidities, postdiagnosis comorbidities
3. Cancer stage Clinical TNM stage, pathological stage
4. Laboratory Prostate-specific antigen, hemoglobin, UDS finding
5. Patient self-reported survey IPSS, IIEF
6. Radiology MRI (initial, follow-up), CT (initial, follow-up), TRUS
7. Pathology Preoperative Bx, postoperative Bx
8. Treatment type Active surveillance, surgery, hormonal therapy, brachytherapy, cryotherapy
9. Medication Medication category, duration, route 
UDS, urodynamic study; IPSS, International Prostate Symptom Score; IIEF, International Index of Erectile Function; MRI, magnetic resonance imaging; 
CT, computed tomography; TRUS, transrectal ultrasonography; Bx, biopsy.
Table 2. Data collection methods of prostate cancer database 
system
Data collection methods Items Percent
Direct electronic medical record extraction 59 26.6
Indirect electronic medical record link 
   (unstructured)
155 69.8
Patient reports 
   (paper or mobile link in future)
8 3.6
Total 222 100
Fig. 1. Clinical data warehouse for electronic medical record 
link. CMC, catholic medical center; ODS, operational data store; 
DW, data warehouse; DB, database; ETL, extraction transaction 
loading .
Clinical data warehouse
ETL
Common DWODS
Prostate 
cancer DB
CMC nU
(oracle 11 g)
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ment. All data and research records are maintained in Inter-
net Data Center which is a facility having telecommunications 
and storage systems, backup power supplies and redundant 
data communications connections. 
 This database system provides three different ways of data 
collection depending on the information technology infra-
structure; direct manual entry; Excel upload, and direct EMR 
link using CDW technology (Fig. 2). For example, a hospital 
A already has affluent human resource for prostate cancer 
registry, and prefers manual entry. Then they can access web 
browser and enter each data field. A hospital prefers to enter 
data into Excel file and later upload Excel file into the web 
system. Other hospital wants to download research data auto-
matically and import the extracted file into the research data 
base system. 
 We implemented CDW technology to test direct EMR link 
method with St. Mary’s Hospital system. We defined the EMR 
variables mapped with the research data elements. Relevant 
data was transferred into the EMR system of St. Mary’s Hos-
pital using CDW technology and extracted data into the pros-
tate cancer database system. To validate CDW technology, we 
selected sample data and compared with EMR system. Using 
this method, total number of eligible patients were 2,300 from 
2008 until 2012. Among them, 538 patients conducted surgery 
and others have different treatments. 
 After completion of the data control for registered patients, 
analytic reports can be prepared for prospective studies and 
research for improved prostate cancer patient care. These 
data summaries evaluate clinical occurrences, patient QoL, 
economic impact, and oncology outcomes, as well as com-
pare types of treatment by stage and practice, among patients 
with prostate cancer in other institutions of Korea. 
 Our system can provide visualization integrating valuable 
information from different data sources. Researchers interpret 
clinical effectiveness in place and can be the turning point in 
uncovering new insights and knowledge about a patient or a 
disease (Fig. 3).
DISCUSSION
Our suggested database structure is applicable for any hospi-
tal which wants to link their EMR system directly with our re-
search system and can be a representative database to under-
stand prostate cancer patients and treatment patters in Korea.
 Our system can provide complete treatment histories and 
patient information and can allow for comparison of different 
outcomes. As the number of enrolled patients is increased, 
the system will contribute to compare primary indicator for 
prostate cancer patients with other institutions in Korea and 
other databases such as CaPSURE from United States and 
J-CaP from Japan. For example, UCSF-CAPRA (University 
of California, San Francisco Cancer of the Prostate Risk As-
sessment) is a risk assessment tool developed from a cohort 
of radical prostatectomy patients (n=1,439) in the CaPSURE 
database. The Japanese tool named as ‘J-CAPRA’ is developed 
for patients undergoing PADT and is applied for those with 
both localized and advanced disease [16].
 The longitudinal observation database is an important 
source to investigate therapeutic efficacy and patient outcomes 
in the real clinical settings and therefore can be an invaluable 
complement of randomized clinical trials. Our database sys-
tem could provide the infrastructure for collecting data on the 
quality of prostate cancer care. Our large database system, like 
J-CaP and CaPSURE, can provide valuable real-world informa-
tion and would help advance clinical management of prostate 
Fig. 3. Patient characteristics by treatment.
Fig. 2. Integrated prostate cancer database system. EMR, elec-
tronic medical record; CDW, clinical data warehouse; MRI, mag-
netic resonance imaging. 
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•  Lobor intensive
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•  Do not share
•  Data transfer using CDW
•  With unstructured data 
   (MRI finding, 
    pathology report, etc.)
•  Entry for unstructured data
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cancer patients in the future.
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